Back to News
Market Impact: 0.35
UroGen Pharma Ltd. Reports Third Quarter 2026 Financial Results and FDA Acceptance of UGN-103 NDA
Source: Nasdaq
Corporate EarningsCompany FundamentalsProduct LaunchesHealthcare & Biotech
UroGen Pharma reported third-quarter 2026 revenue of $89.0 million, up from $27.5 million in the year-earlier quarter. The increase was primarily driven by the commercial launch of ZUSDURI, which generated $68.0 million in net product revenue.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
URGN0.70
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales